Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

254 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase II randomised discontinuation trial of brivanib in patients with advanced solid tumours.
Jones RL, Ratain MJ, O'Dwyer PJ, Siu LL, Jassem J, Medioni J, DeJonge M, Rudin C, Sawyer M, Khayat D, Awada A, de Vos-Geelen JMPGM, Evans TRJ, Obel J, Brockstein B, DeGreve J, Baurain JF, Maki R, D'Adamo D, Dickson M, Undevia S, Geary D, Janisch L, Bedard PL, Abdul Razak AR, Kristeleit R, Vitfell-Rasmussen J, Walters I, Kaye SB, Schwartz G. Jones RL, et al. Among authors: khayat d. Eur J Cancer. 2019 Oct;120:132-139. doi: 10.1016/j.ejca.2019.07.024. Epub 2019 Sep 12. Eur J Cancer. 2019. PMID: 31522033 Free PMC article. Clinical Trial.
Intravenous aflibercept administered in combination with irinotecan, 5-fluorouracil and leucovorin in patients with advanced solid tumours: results from the expansion cohort of a phase I study.
Khayat D, Tejpar S, Spano JP, Verslype C, Bloch J, Vandecaveye V, Assadourian S, Soussan-Lazard K, Cartot-Coton S, Van Cutsem E. Khayat D, et al. Eur J Cancer. 2013 Mar;49(4):790-7. doi: 10.1016/j.ejca.2012.10.012. Epub 2013 Jan 10. Eur J Cancer. 2013. PMID: 23312881 Clinical Trial.
Phase I dose-escalation study of intravenous aflibercept administered in combination with irinotecan, 5-fluorouracil and leucovorin in patients with advanced solid tumours.
Van Cutsem E, Khayat D, Verslype C, Billemont B, Tejpar S, Meric JB, Soussan-Lazard K, Assadourian S, Cartot-Cotton S, Rixe O. Van Cutsem E, et al. Among authors: khayat d. Eur J Cancer. 2013 Jan;49(1):17-24. doi: 10.1016/j.ejca.2012.07.007. Epub 2012 Aug 24. Eur J Cancer. 2013. PMID: 22921183 Clinical Trial.
Final report of the French multicenter phase II study of the nitrosourea fotemustine in 153 evaluable patients with disseminated malignant melanoma including patients with cerebral metastases.
Jacquillat C, Khayat D, Banzet P, Weil M, Fumoleau P, Avril MF, Namer M, Bonneterre J, Kerbrat P, Bonerandi JJ, et al. Jacquillat C, et al. Among authors: khayat d. Cancer. 1990 Nov 1;66(9):1873-8. doi: 10.1002/1097-0142(19901101)66:9<1873::aid-cncr2820660904>3.0.co;2-5. Cancer. 1990. PMID: 2224783 Clinical Trial.
Who should receive a 5-HT3 antagonist?
Kaye SB, Khayat D, Aapro M, Diehl V. Kaye SB, et al. Among authors: khayat d. Lancet. 1992 Oct 31;340(8827):1107-8. doi: 10.1016/0140-6736(92)93138-d. Lancet. 1992. PMID: 1357507 No abstract available.
254 results